Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.

Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, Wilton SD, Buchmeier MJ, Lebleu B, Iversen PL.

Biochem Soc Trans. 2007 Aug;35(Pt 4):826-8. Review.

PMID:
17635157
2.

Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.

Moulton HM, Moulton JD.

Biochim Biophys Acta. 2010 Dec;1798(12):2296-303. doi: 10.1016/j.bbamem.2010.02.012. Epub 2010 Feb 17.

3.

Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice.

Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL, Kole R.

Mol Ther. 2008 Sep;16(9):1624-9. doi: 10.1038/mt.2008.120. Epub 2008 Jun 10.

4.

Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.

Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV.

J Immunol Methods. 2007 Aug 31;325(1-2):114-26. Epub 2007 Jul 27.

PMID:
17673254
5.

Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.

Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B.

J Control Release. 2006 Dec 1;116(3):304-13. Epub 2006 Sep 30.

PMID:
17097177
6.

Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM.

Bioconjug Chem. 2007 Jan-Feb;18(1):50-60.

PMID:
17226957
7.

Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.

Moulton HM, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R.

Ann N Y Acad Sci. 2009 Sep;1175:55-60. doi: 10.1111/j.1749-6632.2009.04976.x.

PMID:
19796077
8.

Cell penetrating peptide conjugates of steric block oligonucleotides.

Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, Iversen PL, Arzumanov AA, Gait MJ.

Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):517-29. Epub 2007 Oct 22. Review.

PMID:
18037527
9.

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.

Shabanpoor F, McClorey G, Saleh AF, Järver P, Wood MJ, Gait MJ.

Nucleic Acids Res. 2015 Jan;43(1):29-39. doi: 10.1093/nar/gku1256. Epub 2014 Dec 2.

10.

Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models.

Burrer R, Neuman BW, Ting JP, Stein DA, Moulton HM, Iversen PL, Kuhn P, Buchmeier MJ.

J Virol. 2007 Jun;81(11):5637-48. Epub 2007 Mar 7.

11.

Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.

McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.

Gene Ther. 2006 Oct;13(19):1373-81. Epub 2006 May 25.

PMID:
16724091
12.

Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.

Yin H, Moulton HM, Betts C, Merritt T, Seow Y, Ashraf S, Wang Q, Boutilier J, Wood MJ.

Mol Ther. 2010 Oct;18(10):1822-9. doi: 10.1038/mt.2010.151. Epub 2010 Aug 10.

13.

Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL.

Bioconjug Chem. 2004 Mar-Apr;15(2):290-9.

PMID:
15025524
14.

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL.

Bioconjug Chem. 2007 Jul-Aug;18(4):1325-31. Epub 2007 Jun 21.

PMID:
17583927
15.

Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.

Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B, Gait MJ.

Nucleic Acids Res. 2008 Nov;36(20):6418-28. doi: 10.1093/nar/gkn671. Epub 2008 Oct 8.

16.

Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies.

Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, Prevot P, Youngblood DS, Iversen PL, Chernomordik LV, Lebleu B.

Nucleic Acids Res. 2008 Nov;36(20):6343-54. doi: 10.1093/nar/gkn541. Epub 2008 Sep 16.

17.

Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers.

Alonso M, Stein DA, Thomann E, Moulton HM, Leong JC, Iversen P, Mourich DV.

J Fish Dis. 2005 Jul;28(7):399-410.

PMID:
16083445
18.

Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.

Tilley LD, Mellbye BL, Puckett SE, Iversen PL, Geller BL.

J Antimicrob Chemother. 2007 Jan;59(1):66-73. Epub 2006 Oct 31.

19.

Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.

Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD.

Mol Ther. 2007 Sep;15(9):1587-92. Epub 2007 Jun 19.

PMID:
17579573
20.

Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.

Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait MJ, Iversen P, Lebleu B.

J Pept Sci. 2008 Apr;14(4):455-60. doi: 10.1002/psc.979. Review.

PMID:
18236382
Items per page

Supplemental Content

Write to the Help Desk